Publications by authors named "Yingfang Feng"

Claim this Profile
S
Single-cell and bulk transcriptomics reveal a CD8 T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma.
Hengqi Liu, Yingfang Feng, Zhengzi Qian, Zheng Song, Ning Zhang

Front Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib.
Yingfang Feng, Yuan Gao, Shaochuan Liu, Tingting Qin, Yan Zhang

Front Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter re: "Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers".
Yingfang Feng, Huilai Zhang, Xianhuo Wang

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter Entitled "Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers".
Yingfang Feng, Huilai Zhang, Xianhuo Wang

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma.
Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li

Expert Opin Biol Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockers.
Yingfang Feng, Meng Gao, Xiyue Xu, Hengqi Liu, Ke Lu

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell Lymphoma.
Xiyue Xu, Yidan Zhang, Yaxiao Lu, Xiaoyan Zhang, Cuicui Zhao, Yingfang Feng

Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.
Yuan Gao, Yingfang Feng, Shaochuan Liu, Yan Zhang, Jing Wang

Cancer Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Shaochuan Liu, Tingting Qin, Zhujun Liu, Jing Wang, Yanan Jia, Yingfang Feng

Cell Death Dis· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis